Advertisement

Pharmacology of Antimicrobial Agents in Preterm Infants

  • J. N. van den Anker
  • G. L. Kearns
  • R. de Groot
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 25)

Abstract

Bacterial infections continue to be a major cause of morbidity and mortality in preterm infants admitted to neonatal intensive care units [1]. Nosocomial infections including septicemia, meningitis, pneumonia or urinary tract infection occur in approximately 18% of neonates with a very low (<1500 g) birth weight. Major pathogens responsible for bacterial infections during the first month of life are Staphylococcus aureus, coagulase-negative staphylococci, en- terococci, group B streptococcus, Escherichia coli, klebsiella, enterobacter, pseu- domonas and other gram-negative bacteria. The combination of prolonged hospitalization, multiple invasive procedures, prolonged positive pressure ventilation, parenteral nutrition, and an impaired host defence is largely responsible for the increased susceptibility of preterm infants for bacterial, viral and fungal infections.

Keywords

Preterm Infant Neonatal Intensive Care Unit Patent Ductus Arteriosus Dose Interval Antimicrob Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Remington JS, Klein JO, eds (1995) Infectious diseases of the fetus & newborn infant. 4th ed. Philadelphia: Saunders.Google Scholar
  2. 2.
    Besunder JB, Reed MD, Blumer JL (1988) Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part 1) Clin Pharmacokinet 14:189–216.Google Scholar
  3. 3.
    Prober CG, Stevenson DK, Benitz WE (1990) The use of antibiotics in neonates weighing less than 1200 grams. Pediatr Infect Dis J 9:111–121.PubMedCrossRefGoogle Scholar
  4. 4.
    Kildoo C, Modanlou HD, Komatsu G, Harralson A, Hodding J (1984) Developmental pattern of gentamicin kinetics in very low birth weight (VLBW) sick infants. Dev Pharmacol Ther 7:345–356.PubMedGoogle Scholar
  5. 5.
    Koren G, Leeder S, Harding E, Jacques D, MacLeod SM (1985) Optimization of gentamicin therapy in very low birth weight infants. Pediatr Pharmacol (New York) 5:79–87.Google Scholar
  6. 6.
    Landers S, Berry PL, Kearns GL, Kaplan SL, Rudolph AJ (1984) Gentamicin disposition and effect on development of renal function in the very low birth weight infant. Dev Pharmacol Ther 7:285–302.PubMedGoogle Scholar
  7. 7.
    Nahata MC, Powell DA, Gregoire RP, et al (1983) Tobramycin kinetics in newborn infants. J Pediatr 103:136–138.PubMedCrossRefGoogle Scholar
  8. 7.
    Nahata MC, Powell DA, Durreil DE, Miller MC, Glazer JP (1984) Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. J Antimicrob Chemother 14:59–65.PubMedCrossRefGoogle Scholar
  9. 7.
    Nahata MC, Powell DA, Durrell DE, Miller MA (1986) Tobramycin pharmacokinetics in very low birth weight infants. Br J Clin Pharmacol 21:325–327.PubMedGoogle Scholar
  10. 10.
    Kuhn RJ, Nahata MC, Powell DA, Bickers RG (1986) Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharmacol 29:635–637.PubMedCrossRefGoogle Scholar
  11. 11.
    Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW (1990) Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 34:265–268.PubMedGoogle Scholar
  12. 12.
    Van den Anker JN, Hop WC, De Groot R, et al (1994) Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 36:578–581.PubMedGoogle Scholar
  13. 13.
    Jacobs RF, Kearns GL (1989) Cefotaxime and desacetylcefotaxime in neonates and children: a review of microbiologic, pharmacokinetic, and clinical experience. Diagn Microbiol Infect Dis 12:93–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Aujard Y, Brion F, Jacqz-Aigrain E, et al (1989) Pharmacokinetics of cefotaxime and desa- cetyl-cefotaxime in the newborn. Diagn Microbiol Infect Dis 12:87–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Kearns GL, Jacobs RF, Thomas BR, Darville TL, Trang JM (1989) Cefotaxime and desace- tyl-cefotaxime pharmacokinetics in very low birth weight neonates. J Pediatr 114:461- 467.PubMedCrossRefGoogle Scholar
  16. 16.
    Gouyon JB, Pechinot A, Safran C, Chretien P, Sandre D, Kazmierczak A (1990) Pharmacokinetics of cefotaxime in preterm infants. Dev Pharmacol Ther 14:29–34.PubMedGoogle Scholar
  17. 17.
    McCracken GH Jr, Siegel JD, Threlkeld N, Thomas M (1983) Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother 23:341–343.PubMedGoogle Scholar
  18. 18.
    McCracken GH Jr, Threlkeld N, Thomas ML (1984) Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother 26:583–584.PubMedGoogle Scholar
  19. 19.
    Van den Anker JN, Schoemaker RC, Hop WC, et al (1995) Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 58:650–659.PubMedCrossRefGoogle Scholar
  20. 20.
    Van den Anker JN, Hop WC, Schoemaker RC, Van der Heijden AJ, Neijens HJ, De Groot R (1995) Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br J Clin Pharmacol 40:439–443.PubMedGoogle Scholar
  21. 21.
    Van den Anker JN, Schoemaker RC, Van der Heijden AJ, Broerse HM, Neijens HJ, De Groot R (1995) Once-daily versus twice-daily administration of ceftazidime in the preterm infant. Antimicrob Agents Chemother 39:2048–2050.PubMedGoogle Scholar
  22. 22.
    Van den Anker JN, Van der Heijden AJ, Hop WC, et al (1995) The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn. Pediatr Res 38:808–811.Google Scholar
  23. 23.
    Reed MD, Kliegman RM, Weiner JS, Huang M, Yamashita TS, Blumer JL (1987) The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 22:360–363.PubMedCrossRefGoogle Scholar
  24. 24.
    Lisby-Sutch SM, Nahata MC (1988) Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 35:637–642.PubMedCrossRefGoogle Scholar
  25. 25.
    Gross JR, Kaplan SL, Kramer WG, Mason EO Jr (1985) Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol (New York) 5:17–22.Google Scholar
  26. 26.
    Leonard MB, Koren G, Stevenson DK, Prober CG (1989) Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 8:282–286.PubMedGoogle Scholar
  27. 27.
    Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD (1990) Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 14:77–83.Google Scholar
  28. 28.
    James A, Koren G, Milliken J, Soldin S, Prober C (1987) Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 31:52–54.PubMedGoogle Scholar
  29. 29.
    De Hoog M, Mouton JW, Van den Anker JN (1995) Why monitor peak vancomycin concentrations? Lancet 345:646.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • J. N. van den Anker
  • G. L. Kearns
  • R. de Groot

There are no affiliations available

Personalised recommendations